[Alpha Tau in Globe Newswire] Alpha Tau receives FDA approval to initiate a trial for patients with recurrent glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology.

Read more here.